最高“猛砍”90%

Core Viewpoint - The valuation of Nohow Health has been drastically reduced by multiple fund companies, reflecting a pessimistic outlook on its prospects for resuming trading after a prolonged suspension of nearly 15 months [1][2][5]. Valuation Adjustments - On June 25, Changcheng Fund announced a new valuation of Nohow Health at HKD 1.20 per share, representing a 91.51% decrease from its last trading price of HKD 14.14 per share [3][5]. - Since mid-last year, over 40 valuation adjustments have been made by various fund companies, with Dachen Fund adjusting its valuation from HKD 10.12 per share to HKD 1.81 per share [7]. Company Background - Nohow Health, once known as "China's first cancer screening stock," was listed on the Hong Kong Stock Exchange in February 2021 and focuses on the development and commercialization of screening products for colorectal, gastric, and cervical cancers [8]. - The company faced serious allegations of financial misconduct, including a report by Capital Watch claiming that its actual sales for 2022 were only CNY 76.95 million, significantly lower than the reported CNY 765 million [8]. Regulatory and Management Issues - Deloitte raised three major concerns regarding Nohow Health's 2023 annual report, questioning the validity of sales transactions and the effectiveness of marketing expenditures [8]. - Nohow Health was suspended from trading on March 28, 2024, due to its inability to publish its annual report on time, and its founder resigned from key positions in December 2024 [8]. Potential Delisting - According to Hong Kong Stock Exchange regulations, if Nohow Health remains suspended for 18 months, it may face mandatory delisting, with only about three months left before this deadline [9].